← Back to screener

Vor Biopharma Inc. VOR

Rank #2289 · Nasdaq · $1.1B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
25.7
P/E
-9.1
P/B
7.08
ROE
-77.6%
Op. Margin
–%
Debt Ratio
31%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -9.1x, P/B 7.08x. Ranks in the top 80% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -77.6%. Ranks in the top 92% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 31%. Ranks in the top 17% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021–$-0.0B$-0.0B$-0.0B–-159
2022–$-0.1B$-0.1B$-0.1B–-45
2023–$-0.1B$-0.1B$0.2B–23
2024–$-0.1B$-0.1B$0.3B–19
2025–$-0.1B$-0.1B$0.2B–31

← See the full screener